Targeted OA treatment at disease sites using a prodrug that releases an antioxidant at the pain-affected joint
Official title: Individualized treatment of osteoarthritis (OA) through local drug activation at disease sites: Treating OA where, and only where, it is needed
Funded at University of Colorado · NIH-11371552 · Data updated 2026-11-12
A new prodrug approach delivers an antioxidant and anti-inflammatory drug directly to osteoarthritis-affected joints to reduce pain and damage with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project start | September 15, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $368,156 |
| NIH project number | 1R21AR086442-01A1 |
| Project ID | NIH-11371552 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with osteoarthritis, particularly those with symptomatic joint pain and evidence of oxidative stress in affected joints.
✕Less likely to help
Patients without OA or without joints showing oxidative stress-driven pathology may not benefit from this approach.
What this research studies
This project focuses on osteoarthritis, a condition causing pain and disability, by using a prodrug that activates only at sites of joint damage. The strategy aims to deliver MMF, an antioxidant and anti-inflammatory agent, specifically where oxidative stress is high, minimizing effects on healthy tissues. If successful, it could provide a safer, more targeted option for managing OA symptoms and protecting joint function. The work leverages prior de-risking from an NINDS-funded program to move toward a potential oral treatment that acts locally at diseased joints.
Why it matters
Potential benefit: Potentially safer, more effective relief of OA symptoms with fewer systemic side effects by targeting diseased joints.
How similar studies have gone: Preclinical work and a related NINDS-supported program have shown promise in site-specific delivery and activation of similar antioxidant/anti-inflammatory compounds.
Where this research is happening
-
University of Colorado
Boulder, United States Active
Researchers
- Principal investigator: Watkins, Linda — University of Colorado
- Study coordinator: Watkins, Linda
Related research
Other NIH-funded projects on the same topics.
-
Novel SRC kinase blocker to slow osteoarthritis and joint pain
A new drug candidate that blocks a specific SRC kinase interaction is being tested to slow osteoarthritis progression and reduce joint pain.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.